NCT01934010 - AM-101 in the Treatment of Post-Acute Tinnitus 1 | Crick

Overview

The purpose of this research study is to test the safety and local tolerance of repeated treatment cycles of AM-101.

This open-label extension study is assessing the safety and local tolerance of repeated treatment cycles of AM-101 in subjects previously treated in the scope of the TACTT2 study (NCT01803646).

Study Type

INTERVENTIONAL

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Enrollment

260

Conditions

Tinnitus

Interventions

AM-101DRUG

AM-101 gel for intratympanic injection

Eligibility

Sex: ALLMin age: 18 YearsMax age: 76 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Completion of TACTT2 study; * Negative pregnancy test (woman of childbearing potential); * Willing and able to attend the study visits during at least one treatment cycle. Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Adverse event leading to treatment discontinuation in TACTT2; * Meniere's Disease, endolymphatic hydrops, acoustic neuroma, severe or fluctuating hearing loss, otitis media, otitis externa, abnormality of tympanic membrane; * Ongoing drug-based therapy for otitis media or otitis externa; * Drug-based therapy known as potentially tinnitus-inducing; * Other treatment of tinnitus; * Drug abuse or alcoholism; * Subjects with psychiatric diseases requiring drug treatment; * Use of antidepressant or anti-anxiety medication; * Any clinically relevant disorder or abnormality in physical examination; * Women who are breast-feeding, pregnant or who are planning to become pregnant during the study; * Women of childbearing potential who are unwilling or unable to practice contraception. Other protocol-defined exclusion criteria may apply.

Locations (1)

Medpace

Cincinnati, Ohio, United States

Outcomes

Primary Outcomes

Frequency of Subjects With a Deterioration of Hearing Threshold at Day 35 (Air Conduction)

Valid for Safety Analysis Set was used. Air conduction: The atmospheric transmission of sound to the inner ear through the external auditory canal and via structures of the middle ear. The ability of hearing is measured in decibel (dB). The hearing threshold, is the lowest sound pressure where the ear can perceive still a sound. The endpoint deterioration of hearing threshold ≥15 dB in two contiguous test frequencies means that hearing worsens ≥15 dB in two neighboring sound frequencies.

Time frame: Day 1 (TV1) to Day 35 (FUV2) of cycle 1

Frequency of Subjects With a Deterioration of Hearing Threshold at Day 119 (Air Conduction)

Valid for Safety Analysis Set was used. Air conduction: The atmospheric transmission of sound to the inner ear through the external auditory canal and via structures of the middle ear. The ability of hearing is measured in decibel (dB). The hearing threshold, is the lowest sound pressure where the ear can perceive still a sound. The endpoint deterioration of hearing threshold ≥15 dB in two contiguous test frequencies means that hearing worsens ≥15 dB in two neighboring sound frequencies.

Time frame: Day 84 (TV4) to Day 119 (FUV5) of cycle 2

Frequency of Subjects With a Deterioration of Hearing Threshold at Day 203 (Air Conduction)

Valid for Safety Analysis Set was used. Air conduction: The atmospheric transmission of sound to the inner ear through the external auditory canal and via structures of the middle ear. The ability of hearing is measured in decibel (dB). The hearing threshold, is the lowest sound pressure where the ear can perceive still a sound. The endpoint deterioration of hearing threshold ≥15 dB in two contiguous test frequencies means that hearing worsens ≥15 dB in two neighboring sound frequencies.

Time frame: Day 168 (TV7) up to Day 203 (FUV8) of cycle 3

Secondary Outcomes

Frequency of Subjects With a Deterioration of Hearing Threshold at Day 84 (Air Conduction)